![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Emergent to Manufacture and Distribute Ridgeback Bio’s Ebanga Ebola Drug in U.S. and Canada
Emergent to Manufacture and Distribute Ridgeback Bio’s Ebanga Ebola Drug in U.S. and Canada
Emergent BioSolutions has inked a deal with Ridgeback Biotherapeutics, which will allow Emergent to manufacture, sell and distribute Ridgeback’s ebola drug, Ebanga (ansuvimab-zykl).
A monoclonal antibody with antiviral activity that is injectable, Ebanga was FDA-approved for the treatment of Ebola in December 2020. The drug was developed under license from the National Institute of Allergy and Infectious Diseases.
Emergent is still working to regain its footing since the high-profile quality failures at its Baltimore, Md. facility led to the halting of its production of COVID-19 vaccines for Johnson & Johnson and AstraZeneca.
Upcoming Events
-
18Jul
-
21Oct